产品
编 号：F609670
分子式：C25H47N9O5
分子量：553.7
分子式：C25H47N9O5
分子量：553.7
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 931395-42-5
产品详情
生物活性：
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
体内研究：
Dusquetide (SGX942) (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.Animal Model:Female nude mice (MCF-7 tumor xenografts)
Dosage:25 mg/kg
Administration:I.v.; days 0, 4, 7, 10, and 14
Result:Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.
Dusquetide (SGX942) is a first-in-class innate defense regulator (IDR). Dusquetide modulates the innate immune response to both PAMPs and DAMPs by binding to p62. Dusquetide shows activity in both reducing inflammation and increasing clearance of bacterial infection. DAMPs: damage-associated molecular patterns; PAMPs: pathogen-associated molecular patterns
体内研究：
Dusquetide (SGX942) (25 mg/kg; i.v.; days 0, 4, 7, 10, and 14) shows no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.Animal Model:Female nude mice (MCF-7 tumor xenografts)
Dosage:25 mg/kg
Administration:I.v.; days 0, 4, 7, 10, and 14
Result:Showed no increase in tumor growth or worsening of survival and a trend towards decreased tumor growth and improvement in survival with radiation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备